stem-cell-research-2017_posters-accepted-abstracts

5 / 18

Page 83
Notes:
conferenceseries.com
Volume 8, Issue 1 (Suppl) J Cell Sci Ther
ISSN: 2157-7013 JCEST, an open access journal Stem Cell Research 2017
March 20-22, 2017
March 20-22, 2017 Orlando, USA
8th World Congress and Expo on
Cell & Stem Cell Research
Bin Wang et al., J Cell Sci Ther 2017, 8:1 (Suppl)
Atargeted drug delivery system for selective deliver of insulin-like growth factor-1 to infarctedmyocardium
to improve stem cell survival
Bin Wang1,2, Ji Zhou1, Yuan Tang2, Andrew C Issekutz3 and Mohammad F Kiani 1
1Widener University, USA
2Temple University, USA
3Dalhousie University, Canada
Stem cell therapy for treating MI has been widely studied, but the clinical applications of these studies have been disappointing,
since current stem cell therapy has shown poor survival and engraftment of the stem cell in the diseased tissue. In this study, a
novel approach was employed to improve the engraftment and viability of transplanted mesenchymal stem cells (MSCs) by selectively
delivering insulin-like growth factor 1 (IGF-1) to the infarcted myocardium. One week after the MI surgery, immunoliposomes
containing IGF-1 were infused into rats via. tail vein and MSCs were injected intramyocardially around MI area. Left ventricular
fractional shortening (FS) was measured as an index of heart contractility. The combination of targeted IGF-1 and MSCs treatment
significantly improved the FS function (2.5% gain) during 3 weeks (no treatment: 8% FS loss, targeted IGF-1: 4% FS loss, MSCs
treatment 8% FS loss). Immunochemical staining shows that both IGF-1 alone and IGF-1+MSCs treatment facilitated vessel regrowth
into the MI area, and much stronger stem cell fluorescence in the IGF-1+MSCs treatment group compared to the MSCs alone
treatment group, indicating that IGF-1 treatment greatly improved the survival of the transplanted stem cells. The combination of
targeted IGF-1 and stem cell transplantation results in a larger recovery in cardiac function compared to either IGF-1 or stem cell
treatment alone. This recovery is probably achieved by targeted IGF-1 improved the stem cell survival and the subsequent stem cell
therapy in the damaged myocardium.
Biography
Bin Wang has completed his PhD from Temple University in 2007 and Postdoctoral studies from Medical College of Georgia. He is the Assistant Professor of
Widener University. He has published more than 30 papers in reputed journals and has been serving as an Editorial Board Member of several reputed journals.